Apaxen has a pipeline of products ready for clinical testing and at discovery and preclinical stages of development for the treatment of diseases associated with inflammation and fibrosis that depend on prolonged enhanced activity of Macrophage Migration Inhibitory Factor (MIF).

Our clinical development program is aimed at confirming efficacy of our therapeutic approach in Pulmonary inflammatory and fibrotic diseases. At a later stage our products will be tested in a broader set of MIF dependent diseases. In this way we intend to optimise the number of patients that could benefit from our novel approach to treating inflammation and auto-immune diseases.